Biopharmaceutical company Incyte Corporation (NASDAQ: INCY) will be reporting results this Tuesday before the bell. Here’s what to look for.

Incyte beat analysts’ revenue expectations last quarter, reporting revenues of $1.27 billion, up 20.9% year on year. It was a satisfactory quarter for the company, with a beat of analysts’ EPS estimates but full-year revenue guidance missing analysts’ expectations significantly.

Is Incyte a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Incyte’s revenue to grow 23.7% year on year, improving from the 16.5% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Incyte has a history of exceeding Wall Street’s expectations.

With Incyte being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unfold for biotechnology stocks. However, investors in the segment have had steady hands going into earnings, with share prices up 1.3% on average over the last month. Incyte is up 2% during the same time .

ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.

AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.